Bringing the fundamentals into focus…
Back to IRADIMED CORPORATION
How IRADIMED CORPORATION stacks up
IRMD · against 1,336 other Healthcare companies
Valuation
49/ 100
Below the middle of the pack.
Ranked #676 of 1,337 · scores higher than 49% of peers
Bars: peers in each 10-point band of the valuation score134 peers with a valuation score of 40–49, including IRMD · Click a bar to see the companies
Why valuation scores 49?
Weighted metrics compared with all Healthcare companies.Its metrics sit close to the Healthcare norm.
- EBITDA yield is close to the peer norm. EBITDA yield: 3.0% vs peer median 4.0%
- Earnings yield is close to the peer norm. Earnings yield: 2.2% vs peer median 1.5%
- more free cash flow for the price paid: stronger than 63% of peers. Free cash flow yield: 2.4% vs peer median 0.0%
Metric by metric
Position: dot = IRMD, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | IRMD | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 1,287 reported | 2.2% | 1.5% | 55% | 30% | |
| EBITDA yieldHigher is better · 1,357 reported | 3.0% | 4.2% | 44% | 50% | |
| Free cash flow yieldHigher is better · 711 reported | 2.4% | -1.0% | 63% | 20% | |
| Book yieldHigher is better · 1,306 reported | 9.8% | 37.9% | 14% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around IRMDScores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score